COP Chemotherapy Protocol
Cyclophosphamide, Vincristine, Prednisolone
Also known as: COP Protocol · High-dose COP · Cyclophosphamide, Oncovin, Prednisone · CVP protocol
Reviewed by the VetSheet Veterinary TeamUpdated Apr 5, 2026Evidence-based veterinary reference
Doses are a clinical reference for licensed veterinary professionals. Always confirm against the current label and the individual patient.
Dosing by species
🌎 NA — North America🌍 EU — Europe
Dogs
| Indication | Dose | Route | Frequency | Duration | Region |
|---|---|---|---|---|---|
| COP Protocol - Induction (Cyclophosphamide) | 250 mg/m2 | PO | q21d | First 6 months | 🌍 EU |
| COP Protocol - Induction (Vincristine) | 0.70 mg/m2 | IV | q7d for 4 weeks, then q21d | First 6 months | 🌍 EU |
| COP Protocol - Induction (Prednisolone) | 2 mg/kg (week 1), 1.5 mg/kg (week 2), 1 mg/kg (week 3), 1 mg/kg thereafter | PO | q24h (weeks 1-3), then q48h | First 6 months | 🌍 EU |
| COP Protocol - Adjunct (Furosemide) | 1 mg/kg | PO | q12h | For 48h (4 doses) concurrent with cyclophosphamide | 🌍 EU |
| COP Protocol - Maintenance after 6 months (Cyclophosphamide) | 250 mg/m2 | PO | q28d | Months 6 to 12 | 🌍 EU |
| COP Protocol - Maintenance after 6 months (Vincristine) | 0.70 mg/m2 | IV | q28d | Months 6 to 12 | 🌍 EU |
| COP Protocol - Maintenance after 6 months (Prednisolone) | 1 mg/kg | PO | q48h | Months 6 to 12 | 🌍 EU |
| Alternative to Cyclophosphamide (Chlorambucil) | 20 mg/m2 | PO | As directed replacing cyclophosphamide | Ongoing | 🌍 EU |
- COP Protocol - Induction (Cyclophosphamide): Administer with Furosemide to prevent haemorrhagic cystitis.
- COP Protocol - Induction (Vincristine): On q21d schedule, give on the same day as cyclophosphamide.
- COP Protocol - Induction (Prednisolone): Tapering dose schedule.
- COP Protocol - Adjunct (Furosemide): Administered to promote diuresis and reduce risk of haemorrhagic cystitis.
- COP Protocol - Maintenance after 6 months (Cyclophosphamide): Stop protocol after 12 months and monitor for relapse.
- COP Protocol - Maintenance after 6 months (Vincristine): Administer with cyclophosphamide.
- COP Protocol - Maintenance after 6 months (Prednisolone): Stop protocol after 12 months and monitor for relapse.
- Alternative to Cyclophosphamide (Chlorambucil): Use if haemorrhagic cystitis develops or if blood is noted on urine dipstick and culture is negative.
Doses are a clinical reference for licensed veterinary professionals. Always confirm against the current label and the individual patient.
Overview
The COP protocol (Cyclophosphamide, Vincristine, Prednisolone) is a combination cytotoxic therapy commonly used in veterinary oncology, primarily for the treatment of lymphoma.
Clinical Warning: Vincristine is a severe vesicant. Extravasation causes severe tissue necrosis.
Clinical Pearl: While most oncologists prefer a CHOP-type protocol, high-dose COP is a highly useful and relatively straightforward protocol for use in a non-specialist setting.
Mechanism of action
The COP protocol utilizes three distinct mechanisms to target neoplastic cells:
- Cyclophosphamide: An alkylating agent that cross-links DNA strands → prevents DNA replication and transcription → induces cell death.
- Vincristine: Binds to tubulin → inhibits microtubule formation and mitotic spindle assembly → arrests cell division in metaphase.
- Prednisolone: A glucocorticoid that binds to specific intracellular receptors → alters gene expression → induces apoptosis in neoplastic lymphocytes.
Safety & warnings
Contraindications
- Severe neutropenia (< 2 x 10^9/L)
- Pre-existing haemorrhagic cystitis
- Known MDR1 mutation (requires extreme caution/dose adjustment for vincristine)
Adverse effects
- Myelosuppression (neutropenia)
- Haemorrhagic cystitis (cyclophosphamide)
- Gastrointestinal toxicity (vomiting, diarrhoea, anorexia)
- Tissue necrosis if extravasated (vincristine)
Precautions
Vesicant Warning: Vincristine is a vesicant. IV catheters must be placed in all cases, and ONLY catheters placed by a clean 'first-stick' should be used.
Myelosuppression: Discontinue cyclophosphamide if neutrophil count decreases to < 2 x 10^9/L. Check weekly and do not resume until > 3 x 10^9/L. If neutropenia recurs, decrease dose by 10-25%.
MDR1 Mutation: Certain breeds (generally Collie type) are very sensitive to vincristine due to the MDR1 mutation; commercial testing is highly recommended prior to treatment.
Clinical Pearl: GI protectants (e.g., Omeprazole 1 mg/kg q12-24h or Ranitidine with sucralfate) are recommended for the first 21 days of the protocol.
Drug interactions
Inhibits hepatic cytochrome P450 enzyme pathway, potentially altering the metabolism and increasing toxicity of chemotherapeutics.
Monitoring
- Haematology (prior to each vincristine treatment)
- Biochemistry (prior to first treatment, then minimum every 6 months)
- Free-catch urine dipstick (prior to each cyclophosphamide administration to check for blood)
- Urine culture (if blood is noted on dipstick)
Pharmacokinetics
Half-life
Absorption
Cyclophosphamide and Prednisolone are well absorbed orally. Vincristine must be given IV.
Distribution
Vincristine binds extensively to tissues. Cyclophosphamide is widely distributed.
Metabolism
Cyclophosphamide requires hepatic activation (CYP450) to active alkylating metabolites. Vincristine is metabolized by the liver.
Elimination
Cyclophosphamide metabolites are excreted in urine (causing local toxicity). Vincristine is primarily excreted in feces via bile.
Overdose
Severe toxicity: Overdose of these chemotherapeutics can lead to fatal myelosuppression, severe gastrointestinal sloughing, sepsis, and death. Extravasation of vincristine causes severe, progressive tissue necrosis requiring immediate management (e.g., hyaluronidase, warm compresses).
Available products
Formulations
- Oral tablets (Cyclophosphamide, Prednisolone, Chlorambucil, Furosemide)
- Intravenous injection (Vincristine)
Veterinary
- Prednisolone tablets (various strengths)
- Furosemide tablets (various strengths)
Human-labeled
- Cyclophosphamide tablets
- Vincristine sulfate injection
- Chlorambucil tablets
Regulatory status
Protocol utilizes a mix of veterinary-approved (prednisolone, furosemide) and human-approved (cyclophosphamide, vincristine) drugs under the cascade.
Administered under the prescribing cascade.
No regulatory data for: 🇺🇸 US · 🇭🇰 HK · 🇹🇼 TW · 🇯🇵 JP · 🇰🇷 KR · 🇦🇺 AU
Storage & stability
Store oral chemotherapeutics in their original, clearly labeled containers away from food and children. Vincristine injection requires refrigeration and protection from light. Follow strict hazardous drug handling protocols.
Client information
Your pet is undergoing a combination chemotherapy protocol called COP.
- Safe Handling: Chemotherapy drugs are excreted in your pet's urine and feces. Wear disposable gloves when handling their waste or cleaning up accidents for at least 48 hours after treatment. Wash hands thoroughly.
- Medication Administration: Never crush or split chemotherapy tablets.
- What to watch for: Monitor closely for signs of infection (lethargy, fever), gastrointestinal upset (vomiting, diarrhea, loss of appetite), or blood in the urine.
- If you notice blood in the urine, stop the cyclophosphamide immediately and contact your veterinarian, as this may indicate bladder irritation (haemorrhagic cystitis).
VetSheet drug reference is intended for licensed veterinary professionals as a clinical decision-support aid, not a substitute for professional judgement or the manufacturer’s current label.